Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021; 71: 209-249
- Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.World J Gastroenterol. 2019; 25: 3704-3721
- Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.Ann Surg Oncol. 2014; 21: 1287-1295
- Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med. 1996; 334: 693-699
- Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence.Liver Transpl. 2005; 11: 1117-1126
- Anatomical versus non-anatomical resection for hepatocellular carcinoma.Br J Surg. 2015; 102: 776-784
- Long-term survival and recurrence after curative resection for hepatocellular carcinoma in patients with chronic hepatitis C virus infection: a multicenter observational study from China.HPB (Oxford). 2020; 22: 1793-1802
- Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma.Surgery. 2014; 156: 651-660
- Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol. 2003; 38: 200-207
- Ultrasonically guided subsegmentectomy.Surg Gynecol Obstet. 1985; 161: 346-350
- Intraoperative fluorescent imaging using indocyanine green for liver mapping and cholangiography.J Hepatobiliary Pancreat Sci. 2010; 17: 590-594
- A simplified method for controlled left hepatectomy.Surgery. 1985; 97: 358-361
- Glissonean pedicle transection method for hepatic resection: a new concept of liver segmentation.J Hepato-Biliary-Pancreatic Surg. 1998; 5: 286-291
- Anatomic vs. non-anatomic liver resection for hepatocellular carcinoma: standard of care or unfilled promises?.Hepatoma Res. 2021; https://doi.org/10.20517/2394-5079.2021.66
- Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.Langenbecks Arch Surg. 2011; 396: 1109-1117
- Recurrence after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis.Asian Pac J Cancer Prev. 2012; 13: 1771-1777
- A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.Ann Surg Oncol. 2012; 19: 3697-3705
- A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence.HPB (Oxford). 2017; 19: 667-674
- A Meta-analysis comparing the effect of anatomical resection vs. non-anatomical resection on the long-term outcomes for patients undergoing hepatic resection for hepatocellular carcinoma.HPB (Oxford). 2017; 19: 843-849
- Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma: A systemic review and meta-analysis.PLoS One. 2017; 12: e0186930
- Anatomic versus non-anatomic resection for hepatocellular carcinoma: a systematic review and meta-analysis.Eur J Surg Oncol. 2018; 44: 927-938
- Is it just a matter of surgical extension to achieve the cure of hepatocarcinoma? A meta-analysis of propensity-matched and randomized studies for anatomic versus parenchyma-sparing liver resection.J Gastrointest Surg. 2021; 25: 94-103
- Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.Asian J Surg. 2021; 44: 1143-1150
- Hepatic function and liver resection.J Gastroenterol Hepatol. 1990; 5: 296-309
- Anterior approach for difficult major right hepatectomy.World J Surg. 1996; 20: 314-318
- Liver handing maneuver: a safe approach to right hepatectomy liver mobilization.J Am Coll Surg. 2001; 193: 109-111
- Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study.Ann Surg. 2006; 244: 194-203
- Anterior approach for right hepatectomy with hanging maneuver for hepatocellular carcinoma: a multi-institutional propensity score-matching study.J Hepatobiliary Pancreat Sci. 2017; 24: 127-136
- The preference for anterior approach major hepatectomy: experience over 3 decades and a propensity score-matching analysis in right hepatectomy for hepatocellular carcinoma.Medicine (Baltimore). 2015; 94: e1385
- Bleeding during hepatectomy can be reduced by clamping the inferior vena cava below the liver.Surgery. 2004; 135: 67-73
- Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial.Ann Surg. 2011; 253: 1102-1110
- Anterior approach combined with infrahepatic inferior vena cava clamping right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled trial.Medicine (Baltimore). 2016; 95: e4159
- Routine anterior approach during right hepatectomy: results of a prospective randomised controlled trial.J Gastrointest Surg. 2012; 16: 1324-1332
- Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.Ann Surg. 2012; 255: 8-17
- Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.Br J Surg. 2002; 89: 418-422
- A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.Ann Surg. 2007; 245: 831-842
- Effects of Long-Term Postoperative Interferon-Alpha Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma.Ann Intern Med. 2001; 134: 963-967
- Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.Hepatology. 2000; 32: 228-232
- Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.Ann Surg. 2015; 261: 56-66
- Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial.Ann Surg. 2018; 268: 943-954
- Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus– related hepatocellular carcinoma: a two-stage longitudinal clinical study.J Clin Oncol. 2013; 31: 3647-3655
- Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial.PLoS One. 2013; 8: e57397
- Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008; 359: 378-390
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2015; 16: 1344-1354
- Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.Jpn J Cancer Res. 2002; 93: 1342-1350
- Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.Asian J Surg. 2016; 39: 149-154
- Capecitabine inhibition of recurrence and metastasis after liver cancer resection in nude mice.Chin Med J. 2001; 39: 199-201
- Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.J Clin Oncol. 2001; 19: 2282-2292
- Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.Clin Cancer Res. 2003; 9: 6030-6037
- Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.Ann Surg Oncol. 2010; 17: 3137-3144
- Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med. 2020; 382: 1894-1905
- Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.J Clin Oncol. 2020; 38: 193-202
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol. 2018; 19: 940-952
- Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial.JAMA Oncol. 2020; 6: e204564
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol. 2022; 23: 77-90
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet. 2017; 389: 2492-2502
- Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.J Clin Oncol. 2022; 40: 416
- IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.Future Oncol. 2020; 16: 975-989
- CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation.Ann Oncol. 2018; 29: viii267-viii268https://doi.org/10.1093/annonc/mdy282.166
- Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet. 2000; 356: 802-807
- A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.Dig Liver Dis. 2009; 41: 36-41
- Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.Gastroenterology. 2015; 148: 1383-13891 e6
- Nodular hepatocellular carcinoma: treatment with subsegmental intraarterial injection of iodine z3 1-labeled iodized Oil.Cancer. 1991; 68: 1878-1884
- Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution.Cancer Chemother Pharmcol. 1992; 31: S128-S136
- lntraarterial Yttrium 90 in the treatment of hepatic malignancy.Radiology. 1982; 142: 783-786
- Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma.Arch Surg. 2000; 135: 1298-1300
- Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial.The Lancet. 1999; 353: 797-801https://doi.org/10.1016/s0140-6736(98)06475-7
- Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.Ann Surg. 2008; 247: 43-48
- Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.World J Surg. 2013; 37: 1356-1361
- Adjuvant Intraarterial Lipiodol or (1)(3)(1)I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial.J Nucl Med. 2014; 55: 877-883
- A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma.J Cancer Res Clin Oncol. 2009; 135: 1437-1445
- TNM classification of malignant tumors.6th edition. Wiley, Hoboken, NJ2002
- Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study.Clin Cancer Res. 2018; 24: 2074-2081
- Is Postoperative adjuvant transcatheter arterial infusion therapy effective for patients with hepatocellular carcinoma who underwent hepatectomy? A prospective randomized controlled trial.Ann Surg Oncol. 2020; 27: 4143-4152
- Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial.Lancet Gastroenterol Hepatol. 2020; 5: 548-560
- Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase III, randomized controlled clinical trial.Ann Surg Oncol. 2020; 27: 5183-5190
- Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (<1 cm): a prospective randomized study.J Am Coll Surg. 2014; 218: 381-392
- Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial.Radiother Oncol. 2019; 140: 20-25
- A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.Ann Surg. 2009; 249: 195-202
- PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.BMC Cancer. 2021; 21: 301
- Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.J Clin Oncol. 2019; 37: 185
- Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study.J Clin Oncol. 2019; 37: 2141-2151
Article info
Publication history
Published online: November 03, 2022
Footnotes
Supported with funding by: 1R01MD012565-01 (A.C. Yopp and N.M. Nevarez).
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
